Molecules that induce tissue factor expression by responsive cells such as endothelial cells and monocytes may be important in the regulation of hemostasis and, perhaps, in mediating certain hemostatic disorders. A constituent of normal human plasma capable of inducing tissue factor activity in human endothelial cells and monocytes has been isolated and identified as a derivative of, or modification associated with albumin. Procoagulant albumin caused a concentrationdependent induction of tissue factor expression by human endothelial cells, but bovine endothelial cells were unresponsive. The dose-response curve developed a plateau phase, ISSUE FACTOR (TF) appears to be the major initia-T tor of blood coagulation in vivo.' Perturbation of responsive cells leads to expression of TF activity.* The subsequent binding of factor VI1 (VIIa) to TF activates factors IX and X, resulting in thrombin generation and fibrin f~rmation.~ Based on the cellular distribution of TF, it has been proposed that intravascular initiation of coagulation requires induced expression of TF by intravascular cells! Because vascular endothelium and monocytes are in continual contact with blood and can be induced to express TF by relevant ~timuli,2,~ these cells may be important in regulation of hemostasis. Known stimuli to cellular expression of TF activity include cytokines (interleukin-1 [IL-1],6 tumor necrosis factor [TNF]'), endotoxin: and t h r~m b i n .~ However, these inducers of T F activity are associated with pathologic states and are not present in normal plasma in amounts adequate for procoagulant activity.
T tor of blood coagulation in vivo.' Perturbation of responsive cells leads to expression of TF activity.* The subsequent binding of factor VI1 (VIIa) to TF activates factors IX and X, resulting in thrombin generation and fibrin f~rmation.~ Based on the cellular distribution of TF, it has been proposed that intravascular initiation of coagulation requires induced expression of TF by intravascular cells! Because vascular endothelium and monocytes are in continual contact with blood and can be induced to express TF by relevant ~timuli,2,~ these cells may be important in regulation of hemostasis. Known stimuli to cellular expression of TF activity include cytokines (interleukin-1 [IL-1],6 tumor necrosis factor [TNF]'), endotoxin: and t h r~m b i n .~ However, these inducers of T F activity are associated with pathologic states and are not present in normal plasma in amounts adequate for procoagulant activity.
In experiments designed to investigate whether activation of complement in human serum would increase cellular T F expression, we observed that small amounts of normal human plasma or serum induced cellular procoagulant (TF) activity in the absence of complement activation. The purpose of this report is to identify and characterize the component of normal human plasma that induces TF activity in endothelial cells and monocytes.
indicating that the capacity of endothelial cells to respond to the stimulus was finite. The maximum response induced by the procoagulant albumin was similar to that observed for maximally effective concentrations of endotoxin, interleukin-1, and tumor necrosisfactor. Time-course studies showed that procoagulant albumin produced peak activity in 4 to 6 hours. Identification of a procoagulant form of albumin in normal human plasma suggests a potential role for this constituent in regulation of hemostasis. 0 1992 by The American Society of Hematology.
MATERIALS AND METHODS
Tissue culture plasticware was obtained from Falcon Plastics (Oxnard, CA). Trizma base, lipopolysaccharide (from Escherichia coli, serotype 055:B5), polymyxin B, an assay kit for endotoxin (E-Toxate), protein A-sepharose CL4B beads, polyethylene glycol (PEG)-4000, ammonium sulfate, human and bovine serum albumins prepared by Cohn fractionation, rabbit brain thromboplastin, and reagents used for buffers and gel electrophoresis were obtained from Sigma Chemical Co (St Louis, MO). An endotoxinaffinity column (Detoxi-Gel) was purchased from Pierce (Rockford, IL). The IgG fraction of goat antihuman albumin was obtained from Atlantic Antibodies (Scarborough, ME). Purified human serum albumin prepared by chromatography on immobilized Cibacron Blue was purchased from Calbiochem (La Jolla, CA). Plasmas deficient in factors VII, VIII, or X were obtained from George King Biomedical (Overland Park, KS). Fetal bovine serum was supplied by HyClone Laboratories, Inc (Logan, UT). Medium 199 (M199) and other tissue culture reagents were provided by the University of California, San Francisco Cell Culture Facility. The chromogenic substrates S-2222 and S-2238 were obtained from KabiVitrum (Franklin, OH). IL-1 and TNF were supplied by Genzyme (Boston, MA). Elution of proteins from gel slices was performed according to the instructions of the manufacturer using a Centrilutor apparatus from Amicon (Beverly, MA).
Human umbilical vein endothelial (HUVE) cells were obtained as described'O and were used between passages 1 and 3. Assays were performed on cells plated in 24-well trays. TF activity induced by column fractions or the purified procoagulant protein was measured by a chromogenic substrate assay" using 100 )LL sample diluted in 400 IJ.L of M199. Optical density readings in this assay were converted to TF activity (mU/well or mU/pg cell protein) using a standard curve derived from results using a commercial thromboplastin preparation in which 1 ~L o f the thromboplastin is equivalent to 1,000 mU of TF activity. The ability of the purified procoagulant protein to induce TF activity in human monocytes was investigated using monocytes prepared by an elutriation method.'* Cellular protein concentrations were determined using the method of Bradford.l3
A hybridoma cell line that produces a monoclonal antibody to human albumin (HSA-1)I4 was provided by Dr David C. Benjamin (University of Virginia, Charlottesville). Hybridoma cells (2 to 3 X lo6) were injected into the peritoneal cavity of pristane-treated BALB-C mice. Ascites fluid was collected and monoclonal antihuman albumin IgG was isolated using caprylic acid. 15 Purification of the procoagulant protein was also monitored by gel electrophoresis. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed as described.l6 Nondenatured gel electrophoresis was also performed." Proteins in gels were identified using a silver-stain kit provided by Bio-Rad (Richmond, CA). Elution of procoagulant activity from a nondenaturing gel was accomplished by electrophoresing 22 pg of the purified, active protein (5.5 pg/lane using four lanes), and obtaining 0.5" gel slices. Individual gel slices were eluted with Tris-buffered saline (TBS) using a Centrilutor apparatus, then assayed for ability to induce TF activity in HUVE cells. Standards of the purified protein and purified human albumin were simultaneously run in separate lanes of the elution experiment and silver-stained to correlate procoagulant activity with gel protein mobility.
Immunoprecipitation experiments were conducted by incubating the IgG fraction of goat antihuman albumin or nonimmune goat IgG with isolated procoagulant albumin in a ratio of 15 moles IgG per 1 mole albumin. Aliquots of 300 pL TBS containing 830 pg/mL of procoagulant albumin and 1 mL TBS containing 28.7 mg/mL of IgG were incubated at 4°C. After 1 hour, 150 p L of TBS containing 25% (vol/vol) protein A-sepharose beads were added, and the incubation was continued at 4°C. As additional controls in these experiments, purified procoagulant albumin was incubated with the suspension of protein A-sepharose beads in the absence of goat IgG, and buffer containing nonimmune IgG was incubated with the suspension of protein A beads in the absence of procoagulant albumin. After 30 minutes, the samples were centrifuged at 8,OOOg for 5 minutes at 21"C, the supernate was recovered, and a second aliquot of 150 pL of 25% protein A-sepharose added. The samples were once again incubated at 4°C for 30 minutes, centrifuged, and the supemates dialyzed against TBS before being assayed for the capacity to induce HUVE cell TF activity.
After washing with 1 mL TBS, the protein A beads were resuspended in reduced SDS-sample buffer and incubated in a boiling water bath. After 5 minutes, the mixture was centrifuged at 8,000g for 5 minutes and the supernate was recovered. These samples along with aliquots of the supernates from the immunoprecipitation studies were analyzed by SDS-PAGE and silver stain.
In a separate experiment, a murine monoclonal antibody (MoAb) to human albumin (HSA-1) was used in an analogous immunoprecipitation study. An MoAb to the platelet glycoprotein IIb-111, complex was used as a control.
Initial purification of the procoagulant protein was accomplished using standard fractionation techniques with BaC12, PEG, and (NH&SO+ Additional purification was achieved using anionexchange (Mono-Q FPLC, Pharmacia-LKB Biotechnology, Inc, Piscataway, NJ), hydroxylapatite (Hydroxylapatite-HT, Bio-Rad, Richmond, CA), and gel filtration (Sephacryl S-200 High Resolution, Pharmacia-LKB Biotechnology, Inc) chromatography. Amino acid sequencing was performed by the University of Utah DNA/ Peptide Facility using an Applied Biosystems gas phase sequenator.
RESULTS
Initial experiments identified procoagulant activity present in normal human plasma or serum. An experiment, in which plasma that had been treated with BaC12 was incubated in varying dilutions with cultured HUVE cells, showed that as little as 5% to 10% plasma induced TF activity (Fig 1) . Similar results were observed when human serum was used; however, bovine serum was without activity when incubated with HUVE cells. Further, when human serum was incubated with bovine endothelial cells, TF activity was not induced, indicating species specificity (data not shown). The dose-response curve developed a plateau when the concentration of plasma was 20%, suggesting that the endothelial cell response was finite.
Isolation of the procoagulant activity was accomplished using fresh-frozen citrated human plasma as the starting material. For every 100 mL plasma, 8 mL of 1 mol/L BaClz was added dropwise and the mixture was stirred on ice for 15 minutes. The precipitate was removed by centrifugation (4,OOOg X 15 minutes, 4°C) and 50% PEG-4,000 in 30 mmol/L Tris base, 100 mmol/L NaCl pH 7.4 was added dropwise to the supernate until a 20% PEG concentration was achieved. This mixture was stirred on ice for 15 minutes and centrifuged at 4, OOOg X 15 minutes at 4°C. The supernate was recovered and a volume of the 50% PEG solution was added until the final PEG concentration of the supernate was 25%. Next, the sample was stirred and centrifuged as described above. The precipitate was discarded, and the 25% PEG supernate was dialyzed against 10 mmol/L Tris base, 10 mmol/L NaCI, pH 8.0 for 3 days with daily change of buffer. Preliminary experiments had shown that the 25% PEG supernate had the highest specific activity; however, the vast majority of the total activity appeared in the 20% and 25% PEG precipitates.
The pH of the dialyzed 25% PEG supernate was adjusted to 8.0 and applied to a Mono-@ column (HR 16/10). The column was washed with 100 mL of 10 mmol/L Tris-HCI, 10 mmol/L NaCI, pH 8.0, and proteins were eluted with a linear salt gradient (10 mmol/L to 500 mmol/L NaCI). Column fractions (3 mL) were collected and assayed for procoagulant activity using the endothelial cell TF bioassay described above. Procoagulant activity consistently eluted in a broad peak with maximal activity seen in fractions eluting with 300 mmol/L NaCl. Analysis of active fractions by reduced and nonreduced SDS-PAGE and by nondenaturing gel electrophoresis is shown in Fig 2. Procoagulant activity was associated with a protein that comigrated with serum albumin on both denaturing and nondenaturing gels.
Additional experiments were performed to confirm the identity of the procoagulant protein. Functional activity could be eluted from a nondenatured gel at a position that correlated with the mobility of the stained band (Fig 3) . An antialbumin antibody immunoprecipitated both procoagulant activity (Table 1 ) and the single band identified by SDS-PAGE (data not shown), but nonimmune IgG did not remove procoagulant activity or the putative albumin band observed by SDS-PAGE. Immunoprecipitation experiments were repeated using the murine MoAb (HSA-1) and a control MoAb. These results (not shown) confirmed the findings of the polyclonal antibody immunoprecipitation. N-terminal amino acid analysis of the purified procoagulant protein showed that the first 20 amino acids had a sequence identical to that of human albumin. These results suggest that either albumin, a modified albumin, or another molecule with a shared epitope to albumin can induce cellular procoagulant activity. Procoagulant activity induced by the purified protein was confirmed as TF using treated cell lysates and factor-deficient plasmas in a recalcification clotting time assay: Procoagulant activity induced by the protein was shown to be dependent on both factors VI1 and X, but not factor VI11 (data not shown), confirming that TF was the procoagulant activity measured.
Based on these results, subsequent purification procedures were directed toward larger-scale isolation of albumin from human plasma using nondenaturing methods. A previously described protocol for (NH&SO4 precipitation of albumin was used.18 Fresh-frozen human plasma was thawed at 37"C, and diluted with an equal volume of water. Solid (NH4)2S04 was added to the diluted plasma to a concentration of 50%, while stirring in an ice bath. The pH of the suspension was maintained at 6.5 using 1 N HCl. After stirring for 15 minutes, the suspension was centrifuged at 4, OOOg for 15 minutes. The supernate was titrated to pH 4.5 using 1 N HCl, stirred for 15 minutes and centrifuged as described above. The precipitate was suspended in 10 mmol/L NaCI, 10 mmol/L Tris-HC1, pH 8.0. The diFolved precipitate was treated with 1 mol/L BaCl2 (8 mL BaC12/100 mL solution), stirred for 15 minutes, and centrifuged. The supernate was dialyzed overnight against 10 mmol/L NaCl, 10 mmol/L Tris-HCI, pH 8.0, then applied to a Mono-Q column. Figure 4A depicts the protein elution and procoagulant activity profiles of this experiment. Reduced and nonreduced SDS-PAGE analysis of the proteins in both the active and inactive fractions is shown in Fig 4B. Both monomeric and multimeric forms of albumin were present in the active fractions. Identity of the high-molecularweight protein as albumin was confirmed using 2-dimensional gel analysis in which samples were electrophoresed under nonreducing conditions in one dimension and under reducing conditions in the second dimension. In the second dimension, the high molecular weight bands appeared off-diagonal in the same horizontal plane as monomeric albumin (data not shown).
Inactive fractions also contained primarily albumin ( Fig  4A) , suggesting that not all albumin has procoagulant activity. When aliquots of inactive albumin were mixed with aliquots of the active material and assayed for TF induction, no inhibition of TF activity was observed, indicating that the inactive material does not act as an inhibitor. The active albumin consistently eluted at a higher salt concentration than the inactive albumin, implying that the modification that imparts procoagulant activity alters the charge of the protein. Procoagulant activity eluted over a broad area, Non -Den at u red 10% Gel fractions after anion-exchange chromatography. Aliquots containing -4pg of protein were subjected to denaturing SDS-PAGE (reduced and nonreduced), and nondenaturing gel electrophoresis. Simultaneously, purified human serum albumin was also analyzed. Silver-stained gels are shown. The electrophoretic mobility of the isolated procoagulant protein is identical to that of albumin. gel. An aliquot of the active material from anion-exchange chromatography containing 22 pg of protein was subjected to nondenaturing gel electrophoresis. The gel was sliced, the protein was eluted from the individual segments and assayed for the capacity to induce TF activity in HUVE cells. A silver-stained gel is shown at the bottom. The lower band is a commercial albumin standard and the upper band is the purified procoagulant protein. Procoagulant activity could be eluted at a gel slice position that corresponded to the mobility of the purified protein and to the mobility of purified human serum albumin. This result is representative of four experiments.
and in most instances, two distinct peaks of activity were observed (Fig 4A) . The latter peak appeared near the end of the gradient in an area where relatively little protein was observed. Together, these observations suggest that procoagulant albumin is heterogeneous, and that a derivative of albumin with prominent anionic properties has particularly high specific activity. To ensure that differences in activity were not the result of higher Salt concentration, in some instances fractions were dialyzed against TBs before the assay. This procedure did not alter the activity profile. Active fractions from the anion-exchange column were Pooled, dialyzed against 10 "ol/L Phosphate buffer, PH 7.09 and chromatographed on hYdrOVlaPatite-All of the Protein bound to the cohmn. After washing with the starting buffer, a linear gradient (10 to 200 "ol/L Phosphate) was applied. Protein eluted in a sharp Peak with a broad shoulder with the peak beginning when the gradient reached approximate1y 30 "OilL phosphate (not shown). The active material eluted over a broad range with activity beginning with the major protein peak, but reaching ing conditions) and silver stain showed that the active A pool of active fractions from the hydroxylapatite column was concentrated by positive pressure ultrafiltration to approximately 14 mL and chromatographed on a 5 x 100 cm column of Sephacryl S-200 that had been equilibrated with TBS. The sample separated into three distinct peaks, with the third peak containing approximately twice as much protein as the first two peaks. While some activity was observed in association with the first two peaks, the majority of the procoagulant activity was Seen in the third peak. Analysis by SDS-PAGE and silver stain (nonreduced and reduced) showed that the first two peaks contained primarily multimeric albumin whereas the last peak contained mostly monomeric albumin. Thus, the modified albumin-inducing procoagulant activity may exist in both a multimeric and monomeric form, although the majority of procoagulant activity is mediated by monomeric albumin.
A summary of an isolation procedure is shown in Table 2 .
steps were dialyzed against TBs and stored at 4°C until completion of the isolation procedure. At that time, all samples were assayed using a single preparation of HUVE column failed to remove procoagulant activity from the sample. Incubation of 100 EU/mL endotoxin in M199 with HUVE cells resulted in induction of 160 mU TF activity, or -9% of the activity seen with the purified protein. Experiments were also performed to investigate possible synergistic induction of TF activity by submaximal concentrations of the purified protein (0.01, 22, 65 pg/mL) and endotoxin (0.1, lpg/mL). Results of these studies indicated that induced TF activity was additive and not synergistic (data not shown). Collectively, these data indicate that although endotoxin is present in the purified, procoagulant albumin preparation, it does not account for the TF activity induced by the purified protein.
Three commercial albumin preparations were assayed for the capacity to induce endothelial cell tissue factor activity. A preparation from Calbiochem that was prepared by chromatography using immobilized Cibacron Blue induced tissue factor activity. However, the specific activity of the preparation was low because maximal procoagulant activity (1,825 mU/well) required a concentration of 8 mg/mL. We have also observed that when serum is chro-matographed on CM-Cibacron Blue 3GA-Agarose (Type 3000-CL, Sigma Chemical Co), procoagulant activity is eluted from the column by 1 mol/L NaCl (along with most of the albumin). Procoagulant activity is also found in the unbound fractions that also contain albumin. Commercial preparations of human and bovine albumin (Sigma Chemical Co) made by the Cohn fractionation method induced no activity at any concentration tested up to 8 mg/mL. This latter observation suggests that the alcohol precipitation method may modify the human albumin in such a way that it loses the capacity to induce tissue factor activity. In other experiments, treatment of procoagulant albumin with 5 mol/L urea, 2 mol/L NaCI, or 10 mmol/L EDTA did not reduce procoagulant activity of the protein. Additionally, procoagulant activity could be eluted from an SDS gel at a position that correlated with the mobility of monomeric albumin. However, these data do not exclude the possibility that a noncovalent modification may be responsible for the procoagulant effect of albumin. Figure 5A depicts the concentration-response relationship observed when incremental amounts of procoagulant albumin were incubated with HUVE cells. Minimally effec- tive concentrations of the protein required to induce T F activity were 5 pg/mL (-1 x mol/L). Maximally effective concentrations of the procoagulant in this assay were 80 to 100 pg/mL. Time-course studies indicated that peak TF activity was induced after 4 to 6 hours, with a slow decrease occurring in TF activity back to basal levels after 12 to 24 hours (Fig 5B) . This time-course result is consistent with the hypothesis that procoagulant albumin induces HUVE cells to synthesize tissue factor.
A comparison of the activity of three known inducers of TF activity (endotoxin, IL-1, and TNF) with that of procoagulant albumin is shown in Fig 6. Maximally effective concentrations6-8 of all inducers were used in this experiment. Procoagulant albumin induced similar amounts of TF activity compared with endotoxin and IL-1, and -70% of the activity induced by TNF.
Inasmuch as monocytes express procoagulant activity in response to relevant pathophysiologic ~t i m u l i ,~ the capacity of procoagulant albumin to induce monocyte TF activity was also investigated. Human monocytes isolated by elutriation were incubated with procoagulant albumin (200 pg/ mL) in M199, or with M199 alone for 4 hours. The monocytes were sedimented by centrifugation, washed, and assayed for TF activity using the chromogenic substrate assay. Monocytes (5 X lo6) incubated with procoagulant albumin expressed 10-fold more TF activity than untreated monocytes, whereas purified inactive albumin (albumin eluted from the anion-exchange column that did not induce endothelial cell TF activity) did not induce monocyte TF activity (Table 3) .
DISCUSSION
The data presented here indicate that a fraction of human plasma albumin possesses the ability to induce procoagulant activity inasmuch as it induces TF expression by W E cells and monocytes. We have performed over 30 purification procedures using either the PEG or (NH&S04 fractionation methods as the initial step in the isolation 2894 FAUCETTE ET AL procedure, and have consistently observed procoagulantinducing activity associated with albumin. The active fraction of albumin is distinguished from the majority of plasma albumin by a difference in charge, with procoagulant albumin exhibiting increased affinity for a positively charged chromatographic matrix (Fig 4A) . Procoagulant albumin can induce TF activity in endothelial cells and monocytes, the two cell types that have been shown to be capable of enhancing expression of TF activity. Induction of TF activity exhibits a time-course relationship similar to that seen with other that is consistent with a requirement for protein synthesis. Further studies are planned to test the hypothesis that TF synthesis is being induced by analyzing TF mRNA from HUVE cells and monocytes that have been treated with procoagulant albumin.
As a result of the purification procedures, greater procoagulant-inducing activity was recovered over that estimated to exist based on activity of starting plasma (Table 2 ). These results suggest that either an inhibitory substance is removed during purification or that the substance is being activated as a result of purification. Further experiments will be required to distinguish between these possibilities.
The modification that engenders albumin with the capacity to induce TF expression in HUVE cells and monocytes remains to be elucidated. Esposito et all9 synthetically glycosylated bovine albumin and reported that it enhanced bovine aortic endothelial cell TF activity. Further, specific receptors for advanced glycosylated proteins have been identified on both rat endothelial cellsm and mouse peritoneal macrophages.21 However, it seems unlikely that the procoagulant property of the albumin identified in the present studies is attributable to glycosylation. The time required for maximal induction of TF activity by the glycosylated bovine albumin prepared by Esposito et a1 was found to be 48 to 60 hours rather than 4 to 6 hours as observed for procoagulant albumin isolated from normal human plasma (Fig 5B) .
Specific binding of albumin to rat endothelial cells has been reported,2O and at least some of the binding appears to be mediated by scavenger receptors." These receptors may have evolved to provide a mechanism by which modified proteins can be removed from circulation. One of the features of ligands recognized by scavenger receptors is that they contain a region with a high density of negatively charged residues.23 Thus, a modification that endows a protein with a highly anionic region may cause it to be recognized by scavenger receptors. Negatively charged substances such as dextran sulfate have been shown to inhibit ligand binding to scavenger receptors, and preliminary studies have shown that dextran sulfate causes a concentration-dependent inhibition of tissue factor activity induced by procoagulant albumin (data not shown). Accordingly, it seems plausable to speculate that a portion of plasma albumin is modified in such a way that it is recognized by scavenger receptors, and that a consequence of this interaction is the induction of TF expression.
Recent studies on the induction of TF activity and its mRNA have identified serum stimulation of the promoter of the TF gene?4,25 Whether or not procoagulant albumin is responsible for this activity is unknown.
Future studies will focus on characterizing the precise modification of albumin that confers the capacity to induce TF expression, identifying molecules that regulate the activity of procoagulant albumin, identifying the receptor on endothelial cells and monocytes that interact with procoagulant albumin, and determining the role of procoagulant albumin in human hemostatic disorders.
